Get the Daily Brief
Latest Biotech News
FDA’s roadmap to replace animal testing accelerates drug evaluation
In April 2025, the FDA unveiled an ambitious plan to phase out animal testing in drug development within three to five years, aiming to adopt more human-relevant methods such as AI-driven...
Breakthrough trispecific antibody shows promise in multiple myeloma
AbbVie licensed ISB 2001, a novel trispecific T-cell engager targeting BCMA, CD38, and CD3, from Ichnos Glenmark Innovation for potentially over $1.9 billion. In a Phase I trial reported at ASCO...
Global proteomics consortium reveals neurodegenerative disease biomarkers
The Global Neurodegeneration Proteomics Consortium (GNPC) published extensive analyses from the largest proteomic dataset to date, encompassing 250 million protein measurements from over 35,000...
Hengrui/Kailera obesity drug delivers significant weight loss in Phase III China trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced positive Phase III results from China for HRS9531, a once-weekly injectable GLP-1/GIP receptor dual agonist. The trial showed...
Waters to acquire BD’s biosciences and diagnostics unit for $17.5 billion
Waters Corporation announced a $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostics Solutions business, expanding Waters into molecular testing and clinical diagnostics. The...
AI-powered open-source RT-LAMP assay offers affordable pathogen detection
A joint research team from Austria and Ghana developed an open-source, freeze-dried reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection optimized...
Takeda’s oral orexin receptor agonist wins Phase III narcolepsy trials
Takeda Pharmaceutical’s oral orexin receptor 2 (OX2R)-selective agonist, oveporexton (TAK-861), achieved all primary and secondary endpoints in two registrational Phase III trials for narcolepsy...
Gilead’s twice-yearly HIV prevention shot gains FDA approval
The FDA approved Gilead Sciences’ Yeztugo (lenacapavir), the first-in-class injectable antiretroviral drug offering nearly complete protection against HIV-1 infection with only two doses per year....
Sino Biopharm acquires majority stake in China’s LaNova Medicines for up to $951 million
Sino Biopharmaceutical announced an agreement to acquire the remaining approximately 95% stake in LaNova Medicines, a Shanghai-based cancer biotech known for PD-1xVEGF bispecific antibodies and...
Novel approach to combat MRSA via bacterial calcification unfolds
A recent Nature Biotechnology publication details a strategy to eradicate methicillin-resistant Staphylococcus aureus (MRSA) infections by inducing calcification on bacterial surfaces, thereby...
Big pharma bets reshape drug discovery landscape
In June 2025, major pharmaceutical companies executed high-profile transactions and collaborations to expand their drug discovery capabilities. Sanofi acquired Blueprint Medicines for $9.1...
Waters to acquire BD biosciences and diagnostics for $17.5B
Waters Corporation announced a $17.5 billion acquisition of Becton Dickinson's Biosciences and Diagnostics Solutions division, aiming to significantly expand its presence in clinical diagnostics...
Hengrui and Kailera report obesity drug phase 3 success in China
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics disclosed positive Phase 3 trial results for their dual GLP-1/GIP receptor agonist obesity drug, HRS9531, in a China-based study....
FDA scrutiny and advisory meetings on GSK's Blenrep for myeloma
GSK's antibody-drug conjugate Blenrep, intended for relapsed/refractory multiple myeloma, faces regulatory uncertainty as the FDA questions sufficiency of data supporting its market re-entry. An...
Global neurodegeneration proteomics consortium releases major datasets
The Global Neurodegeneration Proteomics Consortium (GNPC) unveiled the world's largest proteomic dataset related to dementia, incorporating over 250 million unique protein measurements from more...
Open-source RT-LAMP assay provides low-cost pathogen detection for LMICs
Researchers from the Vienna BioCenter and University of Ghana developed a freeze-dried, open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2...
Ultragenyx gene therapy faces FDA manufacturing rejection
The FDA issued a complete response letter (CRL) to Ultragenyx Pharmaceutical denying approval for its AAV-based gene therapy UX111 for Sanfilippo syndrome type A, due to manufacturing process...
Takeda’s orexin receptor agonist clears Phase 3 trials in narcolepsy
Takeda Pharmaceutical’s oral orexin receptor 2-selective agonist, oveporexton (TAK-861), achieved all primary and secondary endpoints in two Phase 3 trials for narcolepsy type 1. The compound...
Sino Biopharm acquires LaNova Medicines for up to $951M
Chinese pharmaceutical company Sino Biopharmaceutical announced the acquisition of the remaining 95% stake in cancer drug developer LaNova Medicines for up to $951 million. LaNova, based in...
Novel treatments and strategies emerge in cancer and infectious disease
Recent advances include Imugene’s off-the-shelf CD19 CAR T therapy demonstrating a 75% response rate in diffuse large B-cell lymphoma patients during a phase Ib trial, showcasing promise for...